Novel Endocrine Therapy Giredestrant Improves Disease-free Survival Over Standard of Care for Patients With Early-stage Breast Cancer in Phase III lidERA Trial

Kathleen Medora / aacr - SAN ANTONIO – The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with the current standard-of-care endocrine ther…

AI Summary: An international Phase III trial led by UCLA reveals that giredestrant, a novel endocrine therapy, significantly reduces recurrence risk in early‐stage breast cancer compared with standard care. The robust findings promise to shift hormonal treatment paradigms—even if skeptics may raise a wry eyebrow at yet “another” incremental advance in a crowded field.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Therapeutic HPV vaccine slows throat tumors in preclinical tests / 3 months

Gene‑editing trials explore one‑time fix for high cholesterol / 3 months

Bayer’s Asundexian Reduces Stroke Risk by 26% in Phase 3 Trial / 3 months

Eikon Therapeutics raises $381M IPO for cancer drug advancement / 3 months

Aktis Oncology IPO boosts radiopharmaceutical pipeline / 4 months

Tumor bacteria drive head and neck immunotherapy resistance / 4 months

Protego Bio Secures $130M for AL Amyloidosis Therapy Development / 5 months